ARDX · NASDAQ
Ardelyx, Inc.
$3.10 +0.07 (+2.24%)
Company overview
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trials for the treatment of patients with irritable bowel syndrome with constipation, as well as in a Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, an issue among certain patients with kidney and/or heart disease, and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $772M
- Employees
- 395
- Headquarters
- Waltham, MA
- Website
- ardelyx.com
- CEO
- Michael G. Raab
- Listed
- June 19, 2014
- P/E
- -13.18
- Dividend yield
- 0.00%
Company financials
- Revenue
- $428M
- Gross profit
- $393M
- Operating income
- -$37.4M
- EBITDA
- -$34M
- Net income
- -$58.1M
- EPS
- -$0.24
- Total assets
- $505M
- Total debt
- $208M
- Gross margin
- 91.93%
- Net margin
- -13.58%
- Earnings yield
- -7.59%
Showing FY 2025
ARDX
1D
NASDAQ
O3.14H3.14L3.02C3.08-0.12 (-3.75%)Vol1.39M